References Cited in the Evidence Report

1. Salan SZ. Understanding Social Security Disability Programs. Presentation at Multidisciplinary Experts Meeting for the study of Criteria to Determine Disability Related to Multiple Sclerosis, sponsored by the Agency for Healthcare Research & Quality Center for Outcomes and Evidence, Baltimore, MD, March 2003.

2. Social Security Administration. Disability Evaluation under Social Security January 2003. Baltimore, MD: Social Security Administration Office of Disability, 2003; SSA Pub. No. 64-039.

3. World Health Organization. International Classification of Impairments, Disabilities, and Handicaps: A Manual of Classification Relating to the Consequences of Disease. World Health Organization: Geneva, 1980.

4. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13(3):227-31.

5. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50(1):121-7.

6. Jüni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282(11):1054-60.

7. Moher D, Schulz KF, Altman D, for the CONSORT Group. The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285(15):1987-91.

8. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA 2000;283(15):2008-12.

9. Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:602-11.

10. Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. [Review]. Neurology 2000;54(9):1720-5.

11. Bakshi R, Benedict RH, Bermel RA, et al. Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimag 2001;11(2):129-36.

12. Berg D, Maurer M, Warmuth-Metz M, et al. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. Arch Neurol 2000;57(9):1289-92.

13. Catalaa I, Fulton JC, Zhang X, et al. MR imaging quantitation of gray matter involvement in multiple sclerosis and its correlation with disability measures and neurocognitive testing. Am J Neuroradiol 1999;20(9):1613-8.

14. Cercignani M, Inglese M, Pagani E, et al. Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. Am J Neuroradiol 2001;22(5):952-8.

15. Dehmeshki J, Barker GJ, Tofts PS. Classification of disease subgroup and correlation with disease severity using magnetic resonance imaging whole-brain histograms: application to magnetization transfer ratios and multiple sclerosis. IEEE Trans Med Imag 2002;21(4):320-31.

16. Dehmeshki J, Ruto AC, Arridge S, et al. Analysis of MTR histograms in multiple sclerosis using principal components and multiple discriminant analysis. Magnet Reson Med 2001;46(3):600-9.

17. Edwards SG, Gong QY, Liu C, et al. Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis. Brain 1999;122 (Pt 2):291-301.

18. Haughton VM, Yetkin FZ, Rao SM, et al. Quantitative MR in the diagnosis of multiple sclerosis. Magnet Reson Med 1992;26(1):71-8.

19. Hawkins SA. Magnetisation transfer analysis and the disability resulting from multiple sclerosis. J Neurol Neurosurg Psych 2000;69(6):715.

20. Iannucci G, Tortorella C, Rovaris M, et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol 2000;21(6):1034-8.

21. Miller DH. Magnetic resonance imaging and spectroscopy in multiple sclerosis [review]. Curr Opinion Neurol 1995;8(3):210-5.

22. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120 (Pt 11):2059-69.

23. Brex PA, Miszkiel KA, O'Riordan JI, et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. J Neurol Neurosurg Psych 2001;70(3):390-3.

24. CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002;59(7):998-1005.

25. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357(9268):1576-82.

26. Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psych 2002;73(2):141-7.

27. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52(1):47-53.

28. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44(4):635-41.

29. Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999;246(9):770-5.

30. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116 (Pt 1):135-46.

31. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121 (Pt 3):495-503.

32. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. 1997. Neurology 2001;57(12 Suppl 5):S36-45.

33. Sastre-Garriga J, Tintoré M, Rovira A, et al. Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler 2003;9(1):39-43.

34. Tintoré M, Rovira A, Río J, et al. New diagnostic criteria for multiple sclerosis - application in first demyelinating episode. Neurology 2003;60(1):27-30.

35. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38(2):180-5.

36. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988;38(12):1822-5.

37. Ford HL, Johnson MH, Rigby AS. Variation between observers in classifying multiple sclerosis. J Neurol Neurosurg Psych 1996;61(4):418.

38. Zipoli V, Portaccio E, Siracusa G, et al. Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. Mult Scler 2003;9:481-5.

39. Barkhof F, Filippi M, van Waesberghe JH, et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 1997;49(6):1682-8.

40. Barkhof F, Filippi M, van Waesberghe JH, et al. Interobserver agreement for diagnostic MRI criteria in suspected multiple sclerosis. Neuroradiology 1999;41(5):347-50.

41. Chapman J, Sylantiev C, Nisipeanu P, et al. Preliminary observations on APOE epsilon4 allele and progression of disability in multiple sclerosis. Arch Neurol 1999;56(12):1484-7.

42. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 1999a;122 (Pt 4):641-7.

43. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a

geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999b;122 (Pt 4):625-39.

44. Fuhr P, Borggrefe-Chappuis A, Schindler C, et al. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001;124(Pt 11):2162-8.

45. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989;46(10):1107-12.

46. Koziol JA, Wagner S, Sobel DF, et al. Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis. Am J Neuroradiol 2001;22(2):284-91.

47. Nortvedt MW, Riise T, Myhr KM, et al. Quality of life as a predictor for change in disability in MS. Neurology 2000;55(1):51-4.

48. Rovaris M, Comi G, Ladkani D, et al. Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. Am J Neuroradiol 2003;24(1):75-81.

49. Runmarker B, Andersson C, Odén A, et al. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994;241(10):597-604.

50. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51(1):234-8.

51. Trotter JL, Clifford DB, McInnis JE, et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 1989;25(2):172-8.

52. Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002;59(4):555-9.

53. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998;50(2):398-402.

54. Bastianello S, Pozzilli C, D'Andrea F, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994;21(3):266-70.

55. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New Engl J Med 1987;317(7):408-14.

56. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991;41(4):533-9.

57. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2(8604):179-83.

58. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337(8739):441-6.

59. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59(5):679-87.

60. Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.[erratum appears in J Neurol Neurosurg Psychiatry 1994 Apr;57(4):528]. J Neurol Neurosurg Psych 1993;56(11):1217-8.

61. De Castro S, Cartoni D, Millefiorini E, et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995;35(6):627-32.

62. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352(9139):1491-7.

63. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997a;349(9052):589-93.

64. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study. Mult Scler 1997b;3(2):137-41.

65. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000;48(6):885-92.

66. Freeman JA, Thompson AJ, Fitzpatrick R, et al. Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology 2001;57(10):1870-5.

67. Ghezzi A, DiFalco MLC, et al. Clinical controlled randomized trial of azathioprine in multiple sclerosis. In: Gonsette RE, Delmotte P, eds. *Recent Advances in Multiple Sclerosis Therapy*. Amsterdam: Elsevier, 1989.

68. Goodkin DE, Bailly RC, Teetzen ML, et al. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991;41(1):20-5.

69. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37(1):30-40.

70. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360(9350):2018-25.

71. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. New Engl J Med 1983;308(4):173-80.

72. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43(4):655-61.

73. IFNB Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45(7):1277-85.

74. IFNB Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47(4):889-94.

75. Jacobs L, Rudick R, Simon J. Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics. J Neuroimmunol 2000;107(2):167-73.

76. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [erratum appears in Ann Neurol 1996 Sep;40(3):480]. Ann Neurol 1996;39(3):285-94.

77. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50(3):701-8.

78. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995 [classical article]. Neurology 2001;57(12 Suppl 5):S16-24.

79. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001;57(11):1969-75.

80. Khatri BO, McQuillen MP, Harrington GJ, et al. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985;35(3):312-9.

81. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60(1):44-51.

82. Liu C, Blumhardt LD. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psych 1999;67(4):451-6.

83. Liu C, Blumhardt LD. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group. J Neurol Sci 2000;181(1-2):33-7.

84. Liu C, Blumhardt LD. Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis. Mult Scler 2002;8(1):10-4.

85. Milanese C, La Mantia L, Salmaggi A, et al. Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results. Ital J Neurol Sci 1988;9(1):53-7.

86. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244(3):153-9.

87. Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol

1990;27(6):591-605.

88. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001;56(11):1514-22.

89. Patten SB, Metz LM. Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001;7(4):243-8.

90. Patti F, L'Episcopo MR, Cataldi ML, et al. Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study. Acta Neurol Scand 1999;100(5):283-9.

91. Patzold U, Hecker H, Pocklington P. Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients. J Neurol Sci 1982;54(3):377-94.

92. Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996;47(6):1463-8.

93. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.[erratum appears in Lancet 1999 Feb 20;353(9153):678]. Lancet 1998;352(9139):1498-504.

94. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54(5):1145-55.

95. Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physic 1999;111(1):35-44.

96. Rudick RA, Fisher E, Lee JC, et al. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 2000;6(6):365-72.

97. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997;49(2):358-63.

98. Schwartz CE, Coulthard-Morris L, Cole B, et al. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol 1997;54(12):1475-80.

99. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344(8914):9-13.

100. SPECTRIMS Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001;56(11):1496-504.

101. Strasser-Fuchs S, Fazekas F, Deisenhammer F, et al. The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Mult Scler 2000;6 Suppl 2:S9-13.

102. van de Wyngaert FA, Beguin C, D'Hooghe MB, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001;101(4):210-6.

103. Weinstein A, Schwid SI, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999;56(3):319-24.

104. Bass B, Weinshenker B, Rice GP, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988;15(1):15-9.

105. Brar SP, Smith MB, Nelson LM, et al. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehab 1991;72(3):186-9.

106. Cartlidge NE, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974;23(1):17-24.

107. Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehab 2000;81(2):164-9.

108. Eyssette M, Rohmer F, Serratrice G, et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opinion 1988;10(10):699-708.

109. Feldman RG, Kelly-Hayes M, Conomy JP, et al. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology 1978;28(11):1094-8.

110. From A, Heltberg A. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975;51(2):158-66.

111. Gambi D, Rossini PM, Calenda G, et al. Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: a double-blind, crossover study in comparison with placebo. Curr Therapeutic Res 1983;33:835-40.

112. Hauser SL, Doolittle TH, Lopez-Bresnahan M, et al. An antispasticity effect of threonine in multiple sclerosis. Arch Neurol 1992;49(9):923-6.

113. Hoogstraten MC, van der Ploeg RJ, vd Burg W, et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand 1988;77(3):224-30.

114. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psych 2000;68(6):707-12.

115. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58(9):1404-7.

116. Lee A, Patterson V. A double-blind study of L-threonine in patients with spinal spasticity. Acta Neurol Scand 1993;88(5):334-8.

117. Levine IM, Jossmann PB, DeAngelis V. Liorseal, a new muscle relaxant in the treatment of spasticity--a double-blind quantitative evaluation. Dis Nerv System 1977;38(12):1011-5.

118. Livesley E. Effects of electrical neuromuscular stimulation on functional performance in patients with multiple sclerosis. Physiotherapy 1992;78(12):914-7.

119. Mondrup K, Pedersen E. The clinical effect of the GABA-agonist, progabide, on spasticity. Acta Neurol Scand 1984b;69(4):200-6.

120. Mondrup K, Pedersen E. The effect of the GABA-agonist, progabide, on stretch and flexor reflexes and on voluntary power in spastic patients. Acta Neurol Scand 1984a;69(4):191-9.

121. Mueller ME, Gruenthal M, Olson WL, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehab 1997;78(5):521-4.

122. Newman PM, Nogues M, Newman PK, et al. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982;23(1):31-5.

123. Nielsen JF, Sinkjaer T, Jakobsen J. Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study. Mult Scler 1996;2(5):227-32.

124. Ørsnes GB, Sørensen PS, Larsen TK, et al. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 2000;101(4):244-8.

125. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. New Engl J Med 1989;320(23):1517-21.

126. Rice GP. Tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1989;16(4):451.

127. Rinne U. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Therapeutic Res 1980;28:827-36.

128. Rudick RA, Breton D, Krall RL. The GABA-agonist progabide for spasticity in multiple sclerosis. Arch Neurol 1987;44(10):1033-6.

129. Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol 1977;34(7):422-8.

130. Sawa GM, Paty DW. The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979;6(3):351-4.

131. Schmidt RT, Lee RH, Spehlmann R. Treatment of spasticity in multiple sclerosis: comparison of dantrolene sodium and diazepam. Trans Am Neurol Assoc 1975;100:235-7.

132. Schmidt RT, Lee RH, Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psych 1976;39(4):350-6.

133. Smith C, Birnbaum G, Carter JL, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994;44(11 Suppl 9):S34-42; discussion S42-3.

134. Smolenski C, Muff S, Smolenski-Kautz S. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opinion 1981;7(6):374-83.

135. Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of

spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990;28(4):512-5.

136. Stien R, Nordal HJ, Oftedal SI, et al. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987;75(3):190-4.

137. United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994;44(11 Suppl 9):S70-8.

138. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26.

139. Francabandera FL, Holland NJ, Wiesel-Levison P, et al. Multiple sclerosis rehabilitation: inpatient vs. outpatient. Rehab Nurs 1988;13(5):251-3.

140. Freeman JA, Langdon DW, Hobart JC, et al. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 1997;42(2):236-44.

141. O'Hara L, Cadbury H, De SL, et al. Evaluation of the effectiveness of professionally guided self-care for people with multiple sclerosis living in the community: a randomized controlled trial. Clin Rehab 2002;16(2):119-28.

142. Patti F, Ciancio MR, Reggio E, et al. The impact of outpatient rehabilitation on quality of life in multiple sclerosis. J Neurol 2002;249(8):1027-33.

143. Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996;39(4):432-41.

144. Pozzilli C, Brunetti M, Amicosante AM, et al. Home based management in multiple sclerosis: results of a randomised controlled trial. J Neurol Neurosurg Psych 2002;73(3):250-5.

145. Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999;52(1):57-62.

146. Stuifbergen AK, Becker H, Blozis S, et al. A randomized clinical trial of a wellness intervention for women with multiple sclerosis. Arch Phys Med Rehab 2003;84(4):467-76.

147. Wassem R, Dudley W. Symptom management and adjustment of patients with multiple sclerosis: a 4-year longitudinal intervention study. Clin Nurs Res 2003;12(1):102-17.

148. Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psych 2001;70(2):174-9.

149. Crawford JD, McIvor GP. Group psychotherapy: benefits in multiple sclerosis. Arch Phys Med Rehab 1985;66(12):810-3.

150. Foley FW, Bedell JR, LaRocca NG, et al. Efficacy of stress-inoculation training in coping with multiple sclerosis. J Consult Clin Psychol 1987;55(6):919-22.

151. Larcombe NA, Wilson PH. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. Brit J Psych 1984;145:366-71.

152. Mendoza RJ, Pittenger DJ, Weinstein CS. Unit management of depression of patients with multiple sclerosis using cognitive remediation strategies: a preliminary study. Neurorehab Neural Repair 2001;15(1):9-14.

153. Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69(6):942-9.

154. Mohr DC, Likosky W, Bertagnolli A, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol 2000;68(2):356-61.

155. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. New Engl J Med 1985;312(23):1480-2.

156. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psych 1990;147(11):1493-7.

157. Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987;14(3):273-8.

158. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989;46(6):676-80.

159. Geisler MW, Sliwinski M, Coyle PK, et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996;53(2):185-8.

160. Gillson G, Richard TL, Smith RB, et al. A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis. Mult Scler 2002;8(1):30-5.

161. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995;45(11):1956-61.

162. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001;7(6):354-8.

163. Weinshenker BG, Penman M, Bass B, et al. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992;42(8):1468-71.

164. Fredrikson S. Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurol Scand 1996;94(1):31-4.

165. Hilton P, Hertogs K, Stanton SL. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psych 1983;46(9):854-5.

166. Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psych 1998;65(5):778-80.

167. Kinn AC, Larsson PO. Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. Scand J Urol Nephrol 1990;24(2):109-12.

168. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehab 2003;17(1):42-7.

169. Vahtera T, Haaranen M, Viramo-Koskela AL, et al. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehab 1997;11(3):211-9.

170. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996;53(12):1270-5.

171. Lincoln NB, Dent A, Harding J, et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psych 2002;72(1):93-8.

172. Beatty WW, Blanco CR, Wilbanks SL, et al. Demographic, clinical and cognitive characteristics of multiple sclerosis patients who continue to work. J Neurol Rehab 1995;9:167-73.

173. Beukelman DR, Kraft GH, Freal J. Expressive communication disorders in persons with multiple sclerosis: a survey. Arch Phys Med Rehab 1985;66(10):675-7.

174. Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part I: Cost of illness. Can J Neurol Sci 1998a;25(1):23-30.

175. Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part II: Quality of life. Can J Neurol Sci 1998b;25(1):31-8.

176. Dyck I, Jongbloed L. Women with multiple sclerosis and employment issues: a focus on social and institutional environments. Can J Occup Therapy 2000;67(5):337-46.

177. Edgley K, Sullivan M, Dehoux E. A survey of multiple sclerosis: determinants of employment status. Can J Rehabil 1991;4:127-32.

178. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehab 1984;65(3):135-8.

179. Genevie L, Kallos JE, Struening EL. Job retention among people with multiple sclerosis. J Neurol Rehab 1987;1:131-5.

180. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000;6(2):91-8.

181. Grønning M, Hannisdal E, Mellgren SI. Multivariate analyses of factors associated with unemployment in people with multiple sclerosis. J Neurol Neurosurg Psych 1990;53(5):388-90.

182. Gulick EE, Yam M, Touw MM. Work performance by persons with multiple sclerosis: conditions that impede or enable the performance of work. Internat J Nurs Stud 1989;26(4):301-11.

183. Hammond SR, McLeod JG, Macaskill P, et al. Multiple sclerosis in Australia: socioeconomic factors. J Neurol Neurosurg Psych 1996;61(3):311-3.

184. Jacobs LD, Wende KE, Brownscheidle CM, et al. A

profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999;5(5):369-76.

185. Jongbloed L. Factors influencing employment status of women with multiple sclerosis. Can J Rehab 1996;9(213-22).

186. Kornblith AB, La Rocca NG, Baum HM. Employment in individuals with multiple sclerosis. Internat J Rehab Res 1986;9(2):155-65.

187. LaRocca N, Kalb R, Kendall P, et al. The role of disease and demographic factors in the employment of patients with multiple sclerosis. Arch Neurol 1982;39(4):256.

188. Miller DM, Rudick RA, Cutter G, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 2000;57(9):1319-24.

189. Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991;41(5):692-6.

190. Rozin R, Schiff Y, Cooper G, et al. Vocational rehabilitation of multiple sclerosis (MS) patients. I. Analysis of clinical and demographic factors. Internat Rehab Med 1982;4(2):75-9.

191. Rozin R, Schiff Y, Kahana E, et al. Vocational status of multiple sclerosis patients in Israel. Arch Phys Med Rehab 1975;56(7):300-4.

192. Scheinberg L, Holland N, Larocca N, et al. Multiple sclerosis; earning a living. NY State J Med 1980;80(9):1395-400.

193. Verdier-Taillefer MH, Sazdovitch V, Borgel F, et al. Occupational environment as risk factor for unemployment in multiple sclerosis. Acta Neurol Scand 1995;92(1):59-62.

194. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-52.

195. Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models [review]. Health Technol Assess (Winchester, England) 2002;6(10):1-73.

196. Arnold DL, Bouchard JP, Boyle CAJ, et al. Key issues in the diagnosis and treatment of multiple sclerosis-an overview. Neurology 2002;59(6):U2-S33.

197. Baker DG. Multiple sclerosis and thermoregulatory dysfunction. J Appl Physiol 2002;92(5):1779-80.

198. Syndulko K, Jafari M, Woldanski A et al. Effects of temperature in multiple sclerosis: a review of the literature. J Neurol Rehab 1996;10:23-34.

199. Beenakker EA, Oparina TI, Hartgring A, et al. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology 2001;57(5):892-4.

200. Guthrie TC, Nelson DA. Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. [Review]. J Neurol Sci 1995;129(1):1-8.

201. Robinson LR, Kraft GH, Fitts SS, et al. Body cooling may not improve somatosensory pathway function in multiple sclerosis. Am J Phys Med Rehab 1997;76(3):191-6.

202. Capello E, Gardella M, Leandri M, et al. Lowering body temperature with a cooling suit as symptomatic treatment for thermosensitive multiple sclerosis patients. Ital J Neurol Sci 1995;16(8):533-9.

203. Ku YT, Montgomery LD, Lee HC, et al. Physiologic and functional responses of MS patients to body cooling. Am J Phys Med Rehab 2000;79(5):427-34.

204. Shakespeare DT, Young CA, Boggild M. Anti-spasticity agents for multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software.

205. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psych 2002;72(2):179-83.

206. Hill AB. The environment and disease: association or causation? Proc R Soc Med 2003;56(9):856-61.

207. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? [Review]. BMJ 1999;319(7224):1562-5.

208. Rockhill B, Byrne C, Rosner B, et al. Breast cancer risk prediction with a log-incidence model: evaluation of accuracy. J Clin Epid 2003;56(9):856-61.

209. Joy JE, Johnston RB. Multiple sclerosis: current status and strategies for the future. Washington, DC: National Academy Press, 2003.

210. National Multiple Sclerosis Society. About MS. Available at http:www.nationalmssociety.org/about. Accessed on October 16, 2003.

211. Hale TW, Hayghe HV, McNeil JM. Persons with disabilities: labor market activity, 1994. Monthly Lab Rev 1998;Sept:3-12.

212. Smith K, Downs B, O'Connell M. Maternity leave and employment patterns: 1961-1995. Current Population Reports, pp 70-9, U.S. Census Bureau, Washington, DC., 2001. Curr Population Rep 2001;Nov:70-9.

213. Cohen PN, Bianchi SM. Marriage, children, and women's employment: what do we know? Monthly Labor Rev 1999;Dec:22-31.

214. Mitchell JN. Multiple sclerosis and the prospects for employment. J Soc Occup Med 1981;31(4):134-8.

215. Berger JR, Sheremata WA. Persistent neurological deficit precipitated by hot bath test in multiple sclerosis. JAMA 1983;249(13):1751-3.

216. Henke AF, Cohle SD, Cottingham SL. Fatal hyperthermia secondary to sunbathing in a patient with multiple sclerosis. Am J Forensic Med Pathol 2000;21(3):204-6.

217. Kohlmeier RE, DiMaio VJ, Kagan-Hallet K. Fatal hyperthermia in hot baths in individuals with multiple sclerosis. Am J Forensic Med Pathol 2000;21(3):201-3.

218. Lennie P, Van Hemel S. Introduction. In: Visual Impairments Determining Eligibility for Social Security Benefits. National Academy Press: Washington DC, 2002, pp. 31-4.